Status:
TERMINATED
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Neoplasms, Breast
Eligibility:
All Genders
18+ years
Brief Summary
This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.
Eligibility Criteria
Inclusion
- The patient has 18 years of age or older at the time of consent.
- The patient has provided pre-treatment tumor samples for WT1 expression screening and gene expression profiling in the context of the NCT01220128 study.
- The patient has a histologically or cytologically confirmed primary invasive breast cancer.
- The patient has provided written informed consent before any new information or new material is provided to the Sponsor.
- The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
- The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
Exclusion
- Not applicable.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT01476111
Start Date
December 1 2011
End Date
July 1 2014
Last Update
March 9 2015
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Newark, Delaware, United States, 19713
2
GSK Investigational Site
Plantation, Florida, United States, 33324
3
GSK Investigational Site
Charleston, South Carolina, United States, 29414
4
GSK Investigational Site
Amarillo, Texas, United States, 79106